A r t i c l e s CD8 T cells are activated when their T-cell receptor (TCR) recognizes a peptide presented in the context of the cognate MHC-I molecule on an antigen-presenting cell. This interaction is a key element of adaptive immunity for defense against pathogens, for the recognition and elimination of cancer cells, and for the pathogenesis of autoimmune diseases. The ability to identify the peptide-MHC (pMHC) molecules recognized by CD8 T cells is crucial to understanding disease development and to developing specific therapeutic interventions. Characterization of T cells that recognize a given antigen can be assessed through functional analyses of antigen stimulation using cytokine-secretion assays, but these methods require large samples, depend on the secretory capacity of T cells, and are usually of low sensitivity 1 .
A r t i c l e s CD8 T cells are activated when their T-cell receptor (TCR) recognizes a peptide presented in the context of the cognate MHC-I molecule on an antigen-presenting cell. This interaction is a key element of adaptive immunity for defense against pathogens, for the recognition and elimination of cancer cells, and for the pathogenesis of autoimmune diseases. The ability to identify the peptide-MHC (pMHC) molecules recognized by CD8 T cells is crucial to understanding disease development and to developing specific therapeutic interventions. Characterization of T cells that recognize a given antigen can be assessed through functional analyses of antigen stimulation using cytokine-secretion assays, but these methods require large samples, depend on the secretory capacity of T cells, and are usually of low sensitivity 1 .
Antigen-specific T cells have been detected using fluorescently labeled pMHC multimers, avoiding a dependence on secretory capacity and enabling parallel analyses of additional characteristics of T cells by flow cytometry 2 . Currently, MHC multimer-based detection of antigen-responsive T cells is limited by the number of fluorescent or metal tags available for either flow or mass cytometry 3, 4 . Combinatorial encoding based on the application of a specific combination of tags to a given pMHC multimer has been employed to enhance the complexity of fluorescence-based analyses [5] [6] [7] , and more recently of mass-cytometry-based analyses 8 . These advances enabled the parallel screening of up to 109 different pMHC-responsive T cells in single samples. Although the combinatorial encoding principle has enhanced our ability to describe immune interactions, the vast number of peptides potentially presented and the diversity of possible T-cell clones require a broader analytic range. An estimated 100,000-750,000 pMHC class I complexes are expressed for each allelic product (for human leukocyte antigen (HLA)-A and HLA-B loci) 9, 10 , and each individual carries ~10 7 different TCRs 11, 12 , each detecting up to 10 6 variations of a given peptide sequence 13 . Thus, a substantial increase in analytic range is required to comprehensively characterize T-cell recognition of cancer cells for personalized immunotherapeutic strategies, to search for T-cell targets involved in autoimmune disease development, and to identify TCR recognition profiles before clinical application. Here we use pMHC multimers tagged with unique DNA barcodes for parallel detection of >1,000 T-cell specificities in a single sample, and identify rare CD8 T-cell specificities in small clinical samples, including peripheral blood. By replacing fluorescence-based detection of pMHC-TCR interactions with DNA-barcoded reagents, which have the potential for ~10 10 different markers, we remove the limitations in T-cell specificity analyses inherent to combinatorial encoding using fluorescent or metal tags.
RESULTS

Large-scale detection of T-cell specificities
We generated DNA barcode-labeled MHC-I multimer reagents on a dextran backbone that carried the common fluorescent label large-scale detection of antigen-specific t cells using peptide-MHc-i multimers labeled with DNA barcodes Identification of the peptides recognized by individual T cells is important for understanding and treating immune-related diseases. Current cytometry-based approaches are limited to the simultaneous screening of 10-100 distinct T-cell specificities in one sample. Here we use peptide-major histocompatibility complex (MHC) multimers labeled with individual DNA barcodes to screen >1,000 peptide specificities in a single sample, and detect low-frequency CD8 T cells specific for virus-or cancerrestricted antigens. When analyzing T-cell recognition of shared melanoma antigens before and after adoptive cell therapy in melanoma patients, we observe a greater number of melanoma-specific T-cell populations compared with cytometry-based approaches. Furthermore, we detect neoepitope-specific T cells in tumor-infiltrating lymphocytes and peripheral blood from patients with non-small cell lung cancer. Barcode-labeled pMHC multimers enable the combination of functional T-cell analysis with large-scale epitope recognition profiling for the characterization of T-cell recognition in various diseases, including in small clinical samples.
A r t i c l e s phycoerythrin (PE) (Fig. 1a,b) . The DNA barcodes were designed from a set of 240,000 unique 25-mer oligonucleotides with sequences described that have similar amplification properties while maintaining maximum diversity of their identification motifs 14 .
To provide a system adaptable to large library screenings, we applied a combinatorial design of DNA barcodes (Fig. 1c and Supplementary  Tables 1-3 ). Through this design we could generate at least 5.8 × 10 6 different barcodes. To determine the number of unique DNA sequences originating from each pMHC-associated barcode (clonally reduced barcode reads), we incorporated unique molecular identifiers (UMIs) 15 next to the barcode sequence (Fig. 1c) , allowing the clonal reduction of sequences from the amplified product. MHC multimers were generated by addition of average two biotinylated DNA barcodes and 12 pMHC complexes per dextramer backbone. pMHC complexes were generated through UV-induced conditional ligand exchange to synthetic peptides of predicted relevance using methods described previously 16, 17 .
After sorting of MHC multimer-binding T cells using fluorescenceactivated cell sorting (FACS) based on PE fluorescence intensity, the composition of the associated DNA barcodes can be retrieved by DNA amplification and high-throughput sequencing. Sequencing data were processed with the software package 'Barracoda' (http://www.cbs.dtu. dk/services/Barracoda, see Online Methods), to obtain the number of clonally reduced barcode reads assigned to a given sample and pMHC specificity (Fig. 1b) . We used the number of clonally reduced reads for a given pMHC specificity to estimate the frequency of T cells specific for a given epitope, based on the average number of TCR-MHC multimer interactions detected in the total MHC multimer-binding T-cell pool in a given cell sample. This estimate was calculated using the following equation: [(number of DNA barcode reads associated with a specific pMHC)/(number of total barcode reads derived from the same sample)] × % MHC multimer-binding cells among total CD8 T cells (Supplementary Table 4 ).
Feasibility and detection limit for large-scale T-cell analysis
Using DNA barcodes to identify pMHC-TCR interactions enables, in principle, distinction of >10 10 different pMHC complexes in a single sample. However, several factors such as efficient and specific pMHC-TCR interactions, protein concentration and production, and peptide synthesis capabilities limit library sizes. To prove the feasibility of staining antigen-specific T cells in mixtures of >1,000 different pMHC multimers, we compared DNA-barcoded MHC multimers and combinatorial fluorescently labeled MHC multimers to detect T-cell populations responsive to virus or cancer-derived peptides 5, 6 . We tested specific T-cell interactions using PE-labeled MHC multimers with and without an attached DNA barcode. The DNA barcode did not interfere with pMHC multimer binding, and MHC multimers with and without DNA barcodes showed identical staining capacities when staining healthy donor peripheral blood mononuclear cells (PBMCs) or tumor-infiltrating lymphocytes (TILs) from a melanoma patient (detection with HLA-A*0201 cytomegalovirus (CMV) pp65 NLV multimers or HLA-A*0201 hTERT p988 (YLQVNSLQTV) multimers, respectively) ( Supplementary Fig. 1a,b) . Moreover, specific DNA barcodes could be amplified after the isolation of HLA-B*0702 CMV pp65 TPR -multimer-binding T cells from healthy donor PBMCs, either following single MHC multimer staining or after mixture with 999 irrelevant MHC multimers. DNA barcodes associated with irrelevant MHC multimers were not identified ( Supplementary Fig. 1c,d) .
We generated a panel of 1,031 pMHC DNA-barcoded multimers with peptides from diverse antigens, including virus-derived, melanoma-associated 18 , Merkel cell polyomavirus-derived 19 , renal cell carcinoma-associated, and breast cancer-associated antigens (Supplementary Table 5 Table 6 ). We detected few T cell populations specific for peptides other than those derived from viruses ( Fig. 2b and Supplementary Fig. 2a ). Among the virusderived specificities, we detected T cells specific for three epitopes in a sample of 100% PBMCs from the BC260 donor: HLA-B*0702 CMV TPR (4.6% of CD8 T cells), HLA-A*0201 CMV NLV (0.15% of CD8 T cells), and HLA-A*0201 EBV YVL (0.06% of CD8 T cells). In a mixed sample of 20% BC260 PBMCs and 80% BC262 PBMCs, we additionally observed T-cell reactivity toward HLA-A*1101 EBV AVF (0.1% of CD8 T cells) and HLA-A*0201 EBV GLC (0.04% of CD8 T cells) from the BC262 donor. Although the two low-frequency BC260-associated responses, HLA-A*0201 CMV NLV and EBV YVL , were no longer identified, the HLA-B*0702 CMV TPR response remained detectable.
Stepwise fivefold titrations led to a corresponding reduction in the detection of the HLA-B*0702 CMV TPR -associated DNA barcode and a loss of significance in terms of sequence-read numbers at 0.008% of CD8 T cells, corresponding to an average of 20 MHC multimer-positive T cells in a flow cytometry-based assessment ( Fig. 2a-c) .
We then compared T-cell detection by DNA barcode-labeled MHC multimers with flow cytometry-based detection to correlate the outcome of the two detection methods. The estimated frequencies of pMHC-responsive T cells correlated with the frequencies determined by combinatorial fluorescently labeled MHC multimers (Fig. 2d,e) . When the HLA-B*0702 CMV TPR -responsive T cells were assessed in an identical set of samples using a smaller library of DNAbarcoded MHC multimers (n = 110; Supplementary Table 7) , we observed a comparable detection limit (0.001% of CD8 T cells) and correlation with detection by fluorescently labeled MHC multimers (r 2 = 0.999; Supplementary Fig. 3a-d) . Moreover, results from the 1,031 DNA-barcoded MHC multimer library correlated with those from the 110 DNA-barcoded MHC multimer library, both in terms of the estimated frequencies of HLA-B*0702 CMV TPR -specific T cells (r 2 = 0.999) and the clonally reduced read counts (r 2 = 0.805) ( Supplementary Fig. 3d ,e). Improved identification of rare specific T cells using higher cell numbers (10 × 10 6 cells per sample), suggested that larger sample sizes may improve the limit of detection (Fig. 2e) .
Detection of T-cell specificities across different donors
We used the 1,031-MHC multimer library to screen for T-cell reactivity in PBMCs from ten healthy donors with various HLA types (Supplementary Table 6 ). Virus-specific T cells were dominant ( Fig. 3a) and, as expected, T-cell specificity was restricted by the donor's HLA haplotype ( Fig. 3b) : donor BC171 expressed HLA-A*1101, A*0301, B*0702, and B*1501, and the T-cell reactivities detected corresponded to these HLA molecules; samples from HLA-A*0201-positive individuals BC260, 259, 261, 262, 268, 254, and 251 showed variable T-cell reactivity toward HLA-A*0201-restricted virus-derived epitopes; donor BC268 expressed HLA-A*0101 and HLA-B*0801, and showed both CMV-and FLU-specific reactivity restricted to these HLA molecules. Among the ten healthy donors screened, we identified only one response not matching the HLA type of the given individual ( Fig. 3b; HLA-B*0801, HSV pU79 EGR , from donor BC251).
We compared these results to fluorescently labeled pMHC multimers and found that the frequencies of antigen-responsive T cells determined using the two methods correlated well (r 2 = 0.967; Fig. 3c Correlations between antigen-specific T-cell frequencies from analyses of T-cell responses in ten healthy donors using either combinatorial fluorescently labeled pMHC multimers (x axes) or 1,031 DNA-barcoded pMHC multimers (y axes). Each dot represents one specificity. Only T-cell populations that fulfilled the significance criteria for DNA barcode assessment (FDR < 0.1%) or the threshold for fluorescent-based analysis (≥10 events and > 0.002% of CD8 T cells) are plotted. All specificities included in the plot were tested using both a combinatorial encoding analysis and DNA-barcoded MHC multimers. Dots plotted on the axes are nonsignificant for one of the methods.
A r t i c l e s MHC multimers. The five responses detected by flow cytometry but not with DNA-barcoded MHC multimers were present at low frequencies in the analyzed cell samples (<0.01% of CD8 T cells), and four of these were just below the threshold of 0.1% FDR or 1/1,000 input reads in the DNA-barcode based analysis. The five T-cell specificities detected with DNA-barcoded MHC multimers and not with fluorescently labeled MHC multimers are likely to be specific given that they all match the HLA-expression and virus-response profiles of the respective donors. When PBMCs from a subset of six of the same donors were analyzed using a library of 110 DNA-barcoded MHC multimers ( Supplementary Fig. 4 and Supplementary Table 7) , we again observed strong correlations between T-cell reactivities detected using DNA-barcoded MHC multimers and those detected using combinatorial fluorescently labeled MHC multimers (r 2 = 0.985; Supplementary Fig. 4c) , and between results from the 110-versus the 1,031-pMHC libraries (r 2 = 0.951) (Supplementary Fig. 4d,e) . These results suggest that library size does not affect the capacity for detection of specific T cells using DNA-barcoded MHCmultimers considerably.
Detection of tumor-reactive T cells
To demonstrate the feasibility of using DNA-barcoded MHC multimers for the detection of tumor-restricted pMHC-specific T cells, we analyzed the T-cell reactivities in expanded TILs from 11 melanoma patients using an HLA-A*0201-restricted DNA-barcoded pMHC multimer library of 167 melanoma-associated peptides and 8 virus-derived peptides (Supplementary Table 8) , described previously 18, 20 . We detected numerous T-cell populations responsive to melanoma-associated antigens in 8 of the 11 TIL products (Fig. 4a,b) . When the same library of melanoma-associated epitopes was used to analyze T cells in the healthy donor cohort, very few responses were detected (Fig. 3a) . Notably, two patients that did not have T cells specific for HLA-A*0201-restricted peptides were found to be HLA-A*0205-positive upon detailed HLA typing (MM10 and MM11, Supplementary Table 6), supporting previous observations that HLA micropolymorphisms may affect T-cell detection by MHC multimers 21, 22 . T-cell reactivity against several well-known melanoma-associated antigens, such as, MART-1, NY-ESO-1, gp100, and tyrosinase, was also detected. We observed reactivity against all three variants of the MART-1 peptide (ELAGIGILTV, EAAGIGILTV, and AAGIGILTV) within the same TIL samples in patients MM02 and MM03 (Fig. 4b) , possibly reflecting partial crossrecognition of all three peptides from the same T-cell population, a phenomenon that has been described previously [23] [24] [25] [26] . Additionally, T-cell reactivity against two different variants of the gp100 peptide (ITDQVPFSV and IMDQVPFSV) and variants of the NY-ESO-1 peptide (SLLMWITQC and SLLMWITQA) was detected in patient MM01 and MM02, respectively (Fig. 4b) (c) Correlations between antigen-specific T-cell frequencies determined across the 11 different TIL samples from melanoma patients analyzed using combinatorial fluorescently labeled pMHC multimers (x axes) or DNA-barcoded pMHC multimers (y axes). Each dot represents one specificity. Only T-cell populations that fulfilled the significance criteria described in Figure 3c were plotted. All specificities were tested using both a combinatorial fluorescently labeled pMHC multimers and DNA-barcoded pMHC multimers. 0.5-2 × 10 6 TILs were analyzed per sample in both methods. 
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A r t i c l e s in the healthy donor cohort, there was a tight correlation between the frequency of antigen-responsive T cells estimated by association to DNA-barcoded MHC multimers, and that detected using combinatorial fluorescently labeled MHC multimers (r 2 = 0.901; Fig. 4c ).
In the melanoma samples, DNA barcode-based screening resulted in detection of more melanoma-specific T-cell populations (n = 45) compared to screening with fluorescently labeled MHC multimers (n = 16). The additional peptide-restricted populations detected by DNA-barcoded MHC multimers showed a patient-specific pattern that matched the HLA expression and antigen-response signature of the patient (Fig. 4a,b) . The detection of an increased number of tumor-specific T-cell populations suggests that T-cell detection based on DNA barcode-labeled MHC multimers may be less dependent on stringent fluorescence-based separation (Supplementary Fig. 5a,b) .
Detection of tumor-reactive T cells in small clinical samples
One major advantage of multiplex technologies for T-cell detection is the possibility of determining the composition of antigen-specific T cells in small biological samples without the need for lymphocyte expansion. We used the high-throughput screening capacity of DNAbarcoded MHC multimers to study the dynamics of T-cell responses in various samples from two patients with metastatic melanoma participating in a phase 2 trial of adoptive cell therapy using in vitro expanded TILs 27 . We screened for T-cell specificity against a library of virus-and shared melanoma-derived epitopes (328 barcoded pMHC multimers, Supplementary Table 9) 13 in enzymatically digested uncultured tumor fragments (i.e., unexpanded TILs), TILs expanded in vitro from small tumor fragments, dissected from the same metastatic lesion, and peripheral blood obtained before and ~1 month after infusion of expanded TILs. Although very few lymphocytes were available in the melanoma samples directly after enzymatic digest (18,000 and 48,000, respectively, for MM01 and MM02), we detected several melanoma-associated T-cell specificities (Fig. 5a,b) . In MM01, two of these specificities were also detected in the expanded TILs and in peripheral blood after transfer (Fig. 5a) . The composition of T-cell specificities in peripheral blood after adoptive transfer was broadly similar to the composition of the TIL infusion product. In MM02, T-cell specificities detected in peripheral blood after TIL transfer reflected the composition of the TIL infusion product, but additional specificities, which matched those detected in a digested sample taken from a tumor lesion after tumor progression, were also detected (Fig. 5b) . Overall, we detected an increased CD8 T-cell response to melanoma-associated antigens in peripheral blood after adoptive transfer of TILs that reflects T-cell populations detected in both tumor digest samples and expanded TIL products.
Detection of neoepitope-specific T cells
Mutation-derived neoepitopes have been suggested as important targets for tumor rejection mediated by T cells, and the predicted neoepitopes (based on the HLA profile of the patients in those studies) correlates positively with clinical outcome following treatment with immune checkpoint inhibitors 28, 29 . Consequently, efficient tools for identification of neoepitope-restricted T cells are of potential prognostic and therapeutic value. We analyzed samples from two non-small cell lung carcinoma (NSCLC) patients for T-cell recognition of predicted HLA-binding peptide sequences containing cancer-specific mutations. For each patient, a large, personal neoepitope peptide library had been generated 25, 30 (n = 288 and n = 417 for patient L011 and L013, respectively, as described in Online Methods). T-cell reactivity of in vitro-expanded TILs was assessed using both combinatorial fluorescently labeled MHC multimers A r t i c l e s samples into 9 or 13 tubes for L011 and L013, respectively. Results from analyses using combinatorial fluorescently labeled MHC multimers were reported in detail previously 30 , and resulted in detection of one neoepitope-responsive T-cell population in patient L011. Using DNA-barcoded MHC multimers, we observed nine neoepitopespecific T-cell population and one virus-specific T-cell population in these two patients (Fig. 6a,b) . The use of DNA barcode-labeled MHC multimers enabled the screening of the whole library in one tube (4-8 × 10 6 TILs) rather than 9-13 parallel tubes (1 × 10 6 TILs per tube) for the fluorescent-based analysis. The larger number of cells in the initial binding reaction may account for the detection of a greater number of T-cell populations detected using the DNA-barcoded MHC multimers. In patient L013 we analyzed TILs from three different tumor regions, a fragment of adjacent normal lung tissue, and peripheral blood taken at the time of tumor removal. For this patient, T cells specific for three neoepitopes were most prominently detected in peripheral blood (Fig. 6b) 
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A r t i c l e s blood has the potential to ease personalized T-cell therapy approaches and immunomonitoring.
Combining functionality and specificity profiling of T cells
We corroborated the functional capacity of T-cell specificities identified by DNA-barcoded pMHC multimers using cytokine production as a readout. In three healthy donor PBMC samples, we analyzed functional activity toward a pool of 32 different CMV, EBV, and FLUderived peptides (CEF pool) by intracellular cytokine staining (ICS) and subsequently stained with a library of 328 DNA-barcoded pMHC multimers (Supplementary Table 9 and Online Methods). We sorted T cells based on their cytokine secretion profile (IFNγ and TNFα secretion (ICS pos ) or no cytokine secretion (ICS neg )) and found that they matched the T-cell specificity assigned by pMHC multimer screening. Functional reactivity was observed for all virus-specific T cells present in these PBMCs (as detected in parallel by using barcoded pMHC multimers and sorting all multimer-positive T cells). Of 11 virusspecific T-cell populations, eight displayed full functionality, as they were only detected in ICS pos fractions; the remaining three responses were present in both the ICS neg and the ICS pos pools, indicating partial functionality (A1101-EBV EBNA4 AVF and A0201-EBV BMF1 GLC in BC011; and B0801-EBV EBNA3a FLR in BC001) (Fig. 7a) .
Using the same principle, we analyzed the functional reactivity of TILs toward autologous tumor cells in a melanoma patient (Fig. 7b,c) .
We detected eight T-cell populations specific for melanomaassociated HLA-A*0201-restricted T-cell epitopes. These T-cell populations were either exclusively or predominantly detected in the ICS pos population, indicating antigen processing and presentation by tumor cells and the functional capacity of epitope-specific TILs. As expected, the four virus-restricted T-cell populations present in this TIL product were detected only in the ICS neg population. These analyses prove the feasibility for combining T-cell detection using large libraries of DNA-barcoded pMHC multimers with assessment of functional responsiveness upon target recognition.
DISCUSSION
We report herein a technology that enables multi-parallel screening of >1,000 pMHC molecules using DNA-barcoded pMHC multimers. The theoretical complexity of DNA barcode tags exceeds 10 10 (ref. 14) , and the complexity of pMHC-based T-cell analyses may consequently extend greatly beyond the 1,000 pMHC molecules used here. The limitations in scalability are based on the ability to achieve specific TCR-pMHC interactions within a very large pool of different pMHC multimers. The number (or concentration) of other MHC multimers that hinders specific TCR-pMHC multimer interactions might be >10,000-100,000 MHC multimers, but current libraries have not yet reached these numbers. Possible bottlenecks for increased library sizes are the automation of pMHC multimer production, high-throughput peptide synthesis, and microfluidics systems to ensure efficient pMHC interaction with all T cells in a given sample and specific interaction of the TCR with its cognate pMHC recognition motif (which can potentially be outmatched by CD8: MHC-constant-region unspecific interactions). The detection of antigen-specific CD8 T cells using DNA-barcoded MHC multimers provides a detection limit comparable to that of fluorescence-based readouts and correlates tightly with the frequency of antigen-specific T cells found using combinatorial fluorescently labeled MHC multimers. We detected several T-cell populations within the same sample in the frequency range of 20-0.01% of CD8 T cells (Figs. 2-4) , and showed that the limit of detection may be improved by increasing the number of T cells analyzed (Figs. 2e and  6a,b) . Experiments in our cohort of tumor-derived material in particular showed a greater number of T-cell populations detected with DNA barcode-labeled MHC multimers, suggesting that this method is less dependent on stringent fluorescence-based separation owing to sequencing of the pMHC multimer-associated DNA barcode to determine T-cell specificity instead of a fluorescent signal as a single parameter (Supplementary Fig. 5a,b) . This may enable detection of low-avidity T cells, as the DNA barcode label is readily recovered from those sorted T cells that bind specifically to the MHC multimer even while obtaining only a marginally higher fluorescent intensity than the MHC multimer negative population. As tumor-reactive T cells, especially those recognizing shared self-peptide epitopes, often have lower affinity for the pMHC recognition motif compared to virus-specific T cells 31 , an improvement in the level of resolution is a considerable advantage, even though our approach may not differentiate between high and low affinity T-cell specificities. Additionally, the dextran backbone used provides a higher-order multimer (~12) as opposed to the streptavidin-based tetramerization conventionally used for combinatorial fluorescently labeled MHC multimers, and may further assist the detection of low-avidity T cells 32, 33 . The ability to assess T-cell antigen recognition at the relevant disease site is important for monitoring and potential intervention in many human disorders. Previous reports demonstrated loss of antigen recognition after in vitro expansion of T cells 18 , which suggests that direct ex vivo assessments of T-cell reactivity will provide insights into the T-cell specificity at disease sites. For diagnostic purposes and for responseto-therapy monitoring, peripheral blood samples are preferable due to ease of access. However, the limited complexity and reduced screening breadth of MHC multimer-based analysis has prohibited direct detection of tumor antigen-responsive T cells from peripheral blood using large peptide libraries. Here, we showed the feasibility of detecting neoepitope-reactive T cells when screening peripheral blood of patients with large libraries of pMHC multimers (Fig. 6a,b) .
We demonstrate that it is feasible to combine the use of DNAbarcoded MHC multimers with functional analysis. Upon peptide or tumor cell stimulation, we selected cytokine-secreting T cells and showed that functional capacity and target recognition can be assessed in parallel across large peptide libraries (Fig. 7) . Such functional assessments are valuable for understanding which antigens form potential tumor rejection epitopes. A future strategy could combine DNA-barcoded MHC multimer staining with single-cell sorting and gene expression profiling approaches [34] [35] [36] to gather further information on relevant tumor epitopes. The analyses presented herein, based on bulk assessments of T-cell populations, largely reflect the information that can be obtained using fluorescently labeled pMHC multimers (Figs. 2-7) , but represents a quantitative leap in the number of potential epitopes that can be assessed in parallel. Such large-scale analyses are particularly relevant when analyzing T-cell reactivity against tumor antigens based on personalized cancer genomic analyses. In general, this technology enables the assessment of T-cell reactivity at genome-wide levels for various immune-mediated diseases, and may enable T-cell specificity assessments that cover TCR variability.
METHODS
Methods and any associated references are available in the online version of the paper. without further selection. Previous experimental validation of peptide-HLA binding has shown that ~50% of the predicted peptides will bind to HLA molecules with medium to high affinity (defined as >60% of a comparable virus-derived T-cell epitope) 19, 20 .
Other peptide libraries included. In the 1,031 peptides library we included peptide libraries associated with Merkel cell carcinoma and breast cancer. Both of these libraries were selected as previously described 19 , using a combination of SYFPEITHI 47 and netMHC 46 . Thresholds applied: > 19 in SYFPEITHI and < 1,000 in netMHC. All predicted peptides were experimentally validated for MHC binding as described in Rodenko et al. 17 . Peptide libraries associated with melanoma and RCC included previous published T-cell epitopes, identified as described in ref. 18 .
Generation of DNA barcode-labeled peptide-MHC multimer libraries.
Unoccupied SA-binding sites on the DNA barcode-assembled dextran conjugates were used for the co-attachment of biotinylated pMHC molecules. 2.3 pmol pMHC monomer was mixed with 160 × 10 −15 mol DNA-barcoded dextran-conjugate and incubated 30 min at RT. MHC multimers were diluted in PBS with 5.2 µM d-biotin (Avidity, Bio200) to 909 nM and incubated 20 min on ice. DNA-barcoded MHC multimers were either stored for up to 5 d at 4 °C (PBS supplemented with NaN 3 , final concentration 0.02% (w/v)) or for up to 2 months at −80 °C (PBS supplemented with glycerol and BSA, final concentrations 5% and 0.5%, respectively).
Immediately before staining barcode-labeled MHC multimers were centrifuged, 5 min at 3,300g, and pooled (2.3 pmol of each pMHC/sample) to enable the detection of multiple T-cell responses in parallel. If necessary, the volume of the reagent pool was reduced up to 50× by ultrafiltration to obtain a final volume of ~80 µL of MHC multimers: centrifugal concentrators (Vivaspin 20, 100,000 Dalton, Sartorius) were saturated in PBS + 5% BSA by centrifugation until >10 mL had passed through the membrane. Concentrators were washed twice, each time by centrifuging 20 mL PBS through the membrane. The pooled multimers were loaded onto the concentrator and centrifuged, 3,300g, 4 °C, to reach a final concentration of 23 nM for each pMHC in the staining reaction. Any aggregates in the MHC multimer reagent pool were sedimented by centrifugation, 5 min at 3,300g before addition to the cell sample. An aliquot of ~5 µL of the MHC multimer reagent pool was stored at −20 °C for baseline analysis.
Generation of fluorescently labeled pMHC tetramers. MHC tetramers were assembled as previously described 5, 6 with nine fluorescent SA conjugates (SA-PE, SA-APC, SA-PE-Cy7, SA-BV421, SA-BV510, SA-BV605, SA-BV650, SA-PE-CF594, SA-BUV395) (BioLegend, Nordic Biosite, Denmark) to allow two-dimensional staining with fluorescent labels of up to 36 T-cell receptor specificities in parallel.
Peptide-MHC multimer staining. Cryopreserved PBMCs and TILs were thawed and washed in RPMI + 10% FCS. Cells were washed in a barcodecytometry buffer (PBS + 0.5% BSA + 100 µg/mL herring DNA + 2 mM EDTA) and incubated 30 min, 37 °C in the presence of 50 nM dasatinib. 2 × 10 5 -3 × 10 6 cells (except when specifically stated) were incubated, 15 min, 37 °C, with pooled DNA-barcoded multimers in a total volume of 100 µL (final concentration of each distinct pMHC, 23 nM). Next a 5× antibody mix composed of CD8-PerCP (Invitrogen MHCD0831) (final dilution 1/50), dump channel antibodies: CD4-FITC (BD 345768) (final dilution 1/80), CD14-FITC (BD 345784) (final dilution 1/32), CD19-FITC (BD 345776) (final dilution 1/16), CD40-FITC (Serotech MCA1590F) (final dilution 1/40), CD16-FITC (BD 335035) (final dilution 1/64) and a dead cell marker (LIVE/DEAD Fixable Near-IR; Invitrogen L10119) (final dilution 1/1000) was added and incubated 30 min, 4 °C. Cells were washed twice in barcode-cytometry buffer and if not acquired immediately, fixed in 1% paraformaldehyde (PFA). If the cells were not acquired within 24 h they were washed twice more and resuspended in barcode-cytometry buffer. Cells were acquired within a week after multimer staining.
Generation of spiked cell samples. Initially, i.e., just after thawing and washing PBMCs in RPMI + 2% FCS, cells were incubated with 50 nM dasatinib, 30 min, 37 °C and resuspended in RPMI + 10% FCS to 0.2 × 10 6 cells mL −1 . Consecutive fivefold dilutions of PBMCs from one healthy donor into PBMCs from another healthy donor generated seven samples with: 100%, 20%, 4%, 0.8%, 0.16%, 0.032%, and 0.0064% cells derived from the first donor PBMCs. Cells were washed in barcode-cytometry buffer and incubated with multimers and antibodies as described above.
Cells applied for tetramer staining were cryopreserved, thawed, washed, and incubated with dasatinib in the same way as cells stained with barcode-labeled multimers. Tetramer stainings were performed as described previously 5, 6 . Intracellular cytokine staining. Healthy donor PBMCs and TILs were thawed and washed in RPMI + 10% FCS. TILs were rested overnight in Xvivo + 5% human serum at 37 °C and 5% CO 2 , washed and resuspended in X-vivo + 5% human serum. 3 × 10 5 TILs were stimulated with autologous tumor at a 3:1 ratio (TIL/tumor) and 1 µL/mL GolgiPlug (BD, 555029) was added before incubation, 5 h, 37 °C and 5% CO 2 . 1 × 10 6 healthy donor PBMCs were stimulated with an extended CEF peptide pool (jpt, PM-CEF-E) at a concentration of 1 µg/mL of each peptide. After 2 h incubation, 37 °C and 5% CO 2 , 1 µL/mL GolgiPlug (BD, 555029) was added and cells were incubated 4 more hours at 37 °C and 5% CO 2 . TILs and healthy donor PBMCs were washed twice in barcode-cytometry buffer and incubated, 15 min, 37 °C, with pooled DNA-barcoded multimers in a total volume of 100 µL (final concentration of each distinct pMHC, 23 nM). Cells were stained with surface antibodies: FITC-conjugated anti-CD3 antibody (BD 345763) and PerCP-conjugated anti-CD8 antibody (Invitrogen MHCD0831) (final dilution 1/40 of each antibody) and dead cell marker (LIVE/DEAD Fixable Near-IR; Invitrogen L10119) (final dilution 1/1,000) and incubated for 30 min, 4 °C. Cells were washed twice in barcode-cytometry buffer, incubated 30 min-overnight, 4 °C, in fixation buffer (1:4, eBioscience 00-5123-43, to diluent eBioscience 00-5223-56), washed and resuspended in permeabilization buffer (1:10 buffer to water, eBioscience 00-8333-56). Cells were stained with intracellular antibodies: PE-Cy7-conjugated anti-TNFα antibody (BioLegend 502930) and APC-conjugated anti-IFNγ antibody (BD 341117) (final dilution 1/10 of each antibody) and incubated 30 min, 4 °C. Cells were washed in permeabilization buffer and resuspended in barcodecytometry buffer. If the MHC-multimer-stained cells were not acquired immediately, they were resuspended in 1% PFA and washed twice more in barcode-cytometry buffer after 1-24 h. Fixed cells were acquired within a week after staining.
Flow cytometry and cell sorting. Cells stained with DNA-barcoded multimers were sorted on a FACSAria (Aria, Aria-II or AriaFusion) (Becton Dickinson) into tubes containing 200 µL barcode-cytometry buffer (tubes were saturated with PBS + 2% BSA in advance). Using FACSDiva software we gated on single, live CD8 + positive and 'dumped' (CD4, 14, 16, 19 , and 40) negative lymphocytes and sorted all multimer (PE) positive cells within this population. For the samples stained with antibodies for intracellular activation-markers and DNA-barcoded-multimers, we gated on single, live CD8 + /CD3 + lymphocytes. In all ICS experiments we sorted the IFN-γ/TNF-α double-positive and the double-negative population into separate tubes. The sorted cells were centrifuged 10 min, 5,000g, and the buffer was removed. The cell pellet was stored at −80 °C in a minimal amount of residual buffer (<20 µL).
Tetramer-stained cells were acquired on a LSR-II or a LSR-Fortessa flow cytometer (Becton Dickinson). Antigen-specific T cells were identified as described 5, 6 . Briefly, we gated on single, live CD8 + positive and 'dump' (CD4, 14, 16, 19 and 40) negative lymphocytes and selected cells positive in two tetramer channels and negative in the seven remaining tetramer channels.
DNA barcode amplification. Taq PCR Master Mix Kit (Qiagen, 201443) was used for amplification of DNA barcodes using 0.3 µM of appropriate forward and reverse primers comprising Ion Torrent PGM 5′ and 3′ adaptors (A-key and P1-key, respectively). PCR amplification was conducted on isolated cells (in <20 µL of buffer) or on the stored aliquot of the MHC multimer reagent pool (diluted 50,000× in the final PCR) used as baseline to determine the number of DNA barcode reads within a non-processed MHC multimer reagent library. Each sample was assigned a distinct sampleID embedded in the forward primer. PCR was performed under the following conditions: 95 °C 10 min; 36 cycles: 95 °C 30 s, 60 °C 45 s, 72 °C 30 s; and 72 °C 4 min. The PCR products were purified with QIAquick PCR Purification kit (Qiagen, 28104) npg
